Daily Cosmetic Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
A multiregional interrupted time-series analysis quantifies post‑COVID surges and regional shifts in aesthetic procedures. An international consensus introduces a multidimensional Natural Outcomes Framework for hyaluronic acid fillers prioritizing safety and patient-centered results, while a state-of-the-art review maps microneedle advances for transdermal and cosmetic applications alongside key regulatory and scalability hurdles.
Research Themes
- Global shifts in aesthetic procedure utilization after COVID-19
- Safety-centric, multidimensional outcomes framework for HA fillers
- Microneedle technology advances for transdermal and cosmetic delivery
Selected Articles
1. Global post-COVID shifts in leading cosmetic procedures: A multiregional time-series analysis.
Using ISAPS survey data (2017–2024), the authors show an immediate global surge in aesthetic procedures post‑COVID with regional heterogeneity: nonsurgical fat reduction rose worldwide; abdominoplasties increased in the US and Latin America; and Europe saw declines in several procedures. After the spike, cumulative global volumes trended upward.
Impact: Provides quantified, region-specific shifts in procedure demand that inform workforce planning, inventory, and strategic service offerings in aesthetic practices.
Clinical Implications: Clinics can adjust capacity, training, and supply chains toward rising procedures (e.g., nonsurgical fat reduction, abdominoplasty) and anticipate slower demand in Europe for certain services, improving operational resilience post‑pandemic.
Key Findings
- Interrupted time series (2017–2024) showed a significant immediate global increase in aesthetic procedures post‑COVID.
- Nonsurgical fat reduction increased worldwide in the immediate post‑pandemic period.
- Abdominoplasties rose in the US (+Δ92,018) and Latin America (+Δ28,534); Latin America also saw increases in blepharoplasty (+Δ14,218) and rhinoplasty (+Δ19,323).
- Europe experienced declines in surgical liposuction (−Δ6,399), botox injections (−Δ38,033), and chemical peels (−Δ18,577).
- After the initial surge, cumulative global procedural volumes continued an upward trend.
Methodological Strengths
- Multiregional dataset from ISAPS covering 2017–2024
- Interrupted time-series design benchmarking against pre‑pandemic trends
Limitations
- Survey-based aggregate counts may be subject to reporting and selection biases.
- Lack of patient-level covariates limits confounding control and rate standardization.
Future Directions: Incorporate patient-level factors, economic indicators, and healthcare capacity to model drivers of demand and forecast long-term utilization.
This study examines the immediate impact of the COVID-19 pandemic on aesthetic procedural rates, across the United States (US), Latin America, Europe, and Asia. Procedural counts from 2017 to 2024 were extracted from the International Society of Aesthetic Plastic Surgery's global survey. An interrupted time series analysis compared short-term procedural volume rates to pre-pandemic trends for leading cosmetic procedures. Globally, nonsurgical fat reductions increased significantly in the immediate post-pandemic period. In the US and Latin America, abdominoplasties increased (+Δ92,018; +Δ28,534), while blepharoplasties (+Δ14,218) and rhinoplasties (+Δ19,323) increased in Latin America only. Conversely, Europe experienced declines in surgical liposuction (-Δ6399), botox injections (-Δ38,033) and chemical peels (-Δ18,577). Despite regional variability, a sharp universal post-pandemic surge occurred, followed by a sustained upward trend in cumulative global procedural volumes.
2. See, Touch, Feel, and Express: Achieving Safe and Natural Outcomes With HA Fillers-An International Consensus.
An international panel proposes a multidimensional Natural Outcomes Framework for HA fillers, expanding assessment beyond appearance to tactile, experiential, and expressive domains with safety as the foundation. It delineates product, patient, and injector factors and outlines a practical workflow from pre‑treatment through follow‑up.
Impact: Establishes shared terminology and a structured, safety-first workflow to standardize and improve 'natural' outcomes, addressing a key gap in aesthetic practice.
Clinical Implications: Adopting the framework can align expectations, reduce overcorrection, guide biomimetic product selection and technique, and structure follow-up to enhance safety and satisfaction.
Key Findings
- Defines a Natural Outcomes Framework spanning See, Touch, Feel, and Express, with safety as the foundational principle.
- Identifies product, patient, and injector factors that shape natural outcomes and recommends biomimetic, low‑inflammation HA fillers with appropriate rheology.
- Provides a practical clinical workflow from pre‑treatment assessment to follow‑up to guide outcome attainment and evaluation.
Methodological Strengths
- International, multidisciplinary expert consensus drawing on literature, survey, and expert meeting
- Actionable, patient-centered framework with explicit domains and workflow
Limitations
- Consensus-based without prospective validation or quantitative outcome data.
- Potential variability in implementation across settings; conflicts of interest not detailed in the abstract.
Future Directions: Validate the framework with prospective studies linking domain-specific assessments to patient-reported outcomes and complication rates.
BACKGROUND: The concept of "natural outcomes" in filler treatments has been explored in clinical studies and literature, yet remains loosely defined, subjective, and lacks standardized assessment criteria. AIMS: To propose a multidimensional Natural Outcomes Framework to systematically define, assess, and communicate natural outcomes following hyaluronic acid (HA) filler treatment, facilitating attainment of desired results. METHODS: An international aesthetic multidisciplinary panel developed consensus statements and a practical framework for achieving safe and natural outcomes with HA fillers based on insights from a literature review, survey, and expert meeting. RESULTS: This expert consensus emphasizes safety as a foundational aspect of natural outcomes. The framework extends beyond visual outcomes ("See") to encompass tactile ("Touch"), experiential ("Feel") and expressive ("Express") dimensions of naturalness, which can be assessed by various methods. The panel identified three categories of factors affecting natural outcomes: product, patient, and injector factors. Treatment can be optimized by selecting HA fillers with biomimetic design, suitable rheological properties, and low inflammatory potential; ensuring knowledge and technical competency; individualizing treatment plans; and fostering effective communication. A practical clinical workflow was devised to guide the attainment and assessment of safe and natural outcomes from pre-treatment to follow-up. CONCLUSIONS: The Natural Outcomes Framework offers a structured approach to achieving safe and desired outcomes with HA fillers, aligned with this principle: "treat the patient, not the photograph." It promotes patient-practitioner alignment on treatment goals and use of appropriate products based on biomimetic design principles, contributing to the attainment of predictable and satisfying results with aesthetic HA filler treatments.
3. Recent advances in microneedle technology in transdermal drug delivery systems.
This expert review synthesizes design, materials, fabrication, and applications of microneedles, including cosmetics, and highlights enabling tools such as AI and 3D printing. It delineates key development hurdles—safety, toxicity, dimensional control, scalability, and regulatory alignment—on the path to broader clinical and consumer adoption.
Impact: Provides a comprehensive roadmap for translational development of microneedles across medical and cosmetic use-cases, integrating emerging digital and manufacturing technologies.
Clinical Implications: Informs selection of MN designs/materials for indications (including cosmetic actives), anticipates safety and regulatory requirements, and guides pathways toward self-administration and decentralized care.
Key Findings
- Summarizes MN design, (bio)materials, fabrication, optimization, and characterization with applications in vaccination, sustained delivery, biologics, targeted delivery, cosmetics, and advanced therapies.
- Highlights enabling technologies such as computational modeling, AI-driven design, and 3D printing for MN development.
- Identifies critical challenges: dimensional control, safety and toxicity, adequacy, scalability, regulatory compliance, and sustainability.
Methodological Strengths
- Broad, up-to-date synthesis spanning engineering, materials science, and clinical applications
- Critical discussion of translational barriers and regulatory considerations
Limitations
- Narrative expert review without systematic search or meta-analytic synthesis.
- Lacks quantitative benchmarking of performance and safety across MN platforms.
Future Directions: Standardize performance and safety metrics across MN platforms and conduct head-to-head clinical studies, including cosmetic active delivery endpoints.
INTRODUCTION: Transdermal drug delivery systems (TDDs) have abundant advantages over traditional drug administration routes (oral and parenteral), however the barrier function of the stratum corneum limits its application to compounds possessing the obligatory physicochemical characteristics. To overcome limitations of TDD, micro-sized needles can be used. Microneedles (MN), a noninvasive drug delivery system, can disrupt the skin's integrity, generating microchannels that facilitate the efficient infusion of drugs. AREAS COVERED: The review highlights recent advances in microneedle technology in transdermal drug delivery systems. The designing, (bio)materials, classification, fabrication, optimization, and characterization of microneedles are covered. The application of microneedles for vaccination, sustained transdermal delivery, biologics, targeted drug delivery, cosmetics, and advanced therapeutic applications are explored. The involvement computational modeling and AI-driven approaches, 3D printing, etc. is included. The critical challenges in microneedle development, e.g. dimensional concerns, safety, adequacy, toxicity, scalability, regulatory, and sustainability, are also covered. EXPERT OPINION: Developments MN technology have extended the potential of the transdermal drug delivery system, holding potential to transform areas like immunization, chronic disease treatment, pain management, and real-time biomonitoring. In the upcoming decade, drug delivery procedures are expected to prioritize people's ease and self-supervision, decreasing dependence on needles and hospitals; however, supervisory synchronization, maneuver calibration, and sustained novelty will be indispensable for MNs to develop as a standard of care.